Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Juris J Meier

Showing results (11-20 of 144) with videos related to

Pageof 15
Sort By:
Diabetologia|May 22, 2015
Incretin-based therapies: where will we be 50 years from now?Juris J Meier, Michael A Nauck
The Lancet. Diabetes & Endocrinology|February 16, 2016
The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventionsMichael A Nauck, Juris J Meier
Diabetologia|April 12, 2014
Risk of pancreatitis in patients treated with incretin-based therapiesJuris J Meier, Michael A Nauck
Regulatory Peptides|March 23, 2005
Glucagon-like peptide 1 and its derivatives in the treatment of diabetesMichael A Nauck, Juris J Meier
Diabetes/Metabolism Research and Reviews|March 11, 2005
Glucagon-like peptide 1(GLP-1) in biology and pathologyJuris J Meier, Michael A Nauck
Current Opinion in Investigational Drugs (London, England : 2000)|May 12, 2004
The potential role of glucagon-like peptide 1 in diabetesJuris J Meier, Michael A Nauck
Current Diabetes Reports|August 11, 2006
Incretins and the development of type 2 diabetesJuris J Meier, Michael A Nauck
Journal of Diabetes Science and Technology|May 31, 2014
Studying pancreatic risks caused by incretin-based therapies: is it a game? It's not a game!Michael A Nauck, Juris J Meier
Diabetes, Obesity & Metabolism|January 5, 2019
Heart failure and type 2 diabetes: From cardiovascular outcome trials, with hopeDario Giugliano, Juris J Meier, Katherine Esposito
Deutsches Arzteblatt International|July 27, 2012
Inpatient treatment of type 2 diabetesThomas G K Breuer, Juris J Meier
Pageof 15

Showing results (11-20 of 144) with videos related to

Sort By:
Pageof 15
Diabetologia|May 22, 2015
Incretin-based therapies: where will we be 50 years from now?Juris J Meier, Michael A Nauck
The Lancet. Diabetes & Endocrinology|February 16, 2016
The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventionsMichael A Nauck, Juris J Meier
Diabetologia|April 12, 2014
Risk of pancreatitis in patients treated with incretin-based therapiesJuris J Meier, Michael A Nauck
Regulatory Peptides|March 23, 2005
Glucagon-like peptide 1 and its derivatives in the treatment of diabetesMichael A Nauck, Juris J Meier
Diabetes/Metabolism Research and Reviews|March 11, 2005
Glucagon-like peptide 1(GLP-1) in biology and pathologyJuris J Meier, Michael A Nauck
Current Opinion in Investigational Drugs (London, England : 2000)|May 12, 2004
The potential role of glucagon-like peptide 1 in diabetesJuris J Meier, Michael A Nauck
Current Diabetes Reports|August 11, 2006
Incretins and the development of type 2 diabetesJuris J Meier, Michael A Nauck
Journal of Diabetes Science and Technology|May 31, 2014
Studying pancreatic risks caused by incretin-based therapies: is it a game? It's not a game!Michael A Nauck, Juris J Meier
Diabetes, Obesity & Metabolism|January 5, 2019
Heart failure and type 2 diabetes: From cardiovascular outcome trials, with hopeDario Giugliano, Juris J Meier, Katherine Esposito
Deutsches Arzteblatt International|July 27, 2012
Inpatient treatment of type 2 diabetesThomas G K Breuer, Juris J Meier
Pageof 15